RVL Pharmaceuticals Plc engages in the development and commercialization of products for neurology and women's health. Its products include Upneeq, M-72, Arbaclofen ER, OS870, Divigel, OB Complete, Methylphenidate ER, Venlafaxine ER tablets (VERT), Hydromorphone ER, Sodium Benzoate/Sodium Phenylacetate, Oxybutynin ER, Prescription Prenatal Vitamins, Chlorzoxazone (Lorzone AG), Tramadol ER (ConZip AG), Nitrofurantoin and Osmodex ANDAs. The company was founded in 1986 and is headquartered in Bridgewater, NJ.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of RVL Pharmaceuticals plc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. RVL Pharmaceuticals plc market cap is $100.00.
What is the 52-week high for RVL Pharmaceuticals plc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. RVL Pharmaceuticals plc 52 week high is $0.0002 as of October 10, 2025.
What is the 52-week low for RVL Pharmaceuticals plc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. RVL Pharmaceuticals plc 52 week low is $0.00 as of October 10, 2025.
What is the 50-day moving average of RVL Pharmaceuticals plc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. RVL Pharmaceuticals plc 50-day moving average is $0.00.